analytics

Illinois: Impact Of Medical Cannabis On Patients To Be Evaluated

RevolutionEnterprisesFlowers

The choices, attitudes, and experience of medical cannabis patients in Illinois will be documented in a first-of-its-kind study through January 8.

Revolution Cannabis Analytics, a newly formed division of Revolution Enterprises, an Illinois-based company that manages two state-of-the-art cannabis cultivation and laboratory facilities in Central Illinois, will perform the study.

Revolution Enterprises said it formed Revolution Cannabis Analytics "to better understand the unique effects of cannabinoids and the types of relief they may provide to patients suffering from certain conditions." Certain cannabinoids, a class of compounds found in the cannabis plant, may be beneficial in the treatment of various health conditions, according to a growing body of research.

Illinois, which allowed for the first sales of legal cannabis Nov. 9, has 3,600 registered patients for the state's pilot program, according to the Illinois Department of Public Health. In addition, almost 29,300 persons with debilitating conditions have started the patient application process since IDPH began accepting applications on Sept. 2, 2014, data show.

"By using information captured through Revolution Cannabis Analytics, we will create the next generation of Revolution genetic varieties to precisely address specific debilitating conditions," said Revolution Enterprises CEO Tim McGraw. "This program will help Illinois to lead the world in the collection of analytical data and patient feedback as it relates to the science of cannabis."

New Mexico: Steep Hill Receives First Provisional Approval For Lab Cannabis Testing

SteepHill(logo)

Steep Hill, which specializes in cannabis testing and analytics in the United States and internationally, has announced intends to open a full service medical cannabis quality assurance laboratory in Albuquerque, New Mexico, bringing advanced scientific tools and methodology to the state, for regulatory oversight of cannabis.

Steep Hill is currently the only laboratory licensed by the New Mexico Department of Health to conduct potency and contaminant testing in order to meet the recently adopted regulatory requirements pertaining to cannabis safety for medical patients in New Mexico, according to a prepared statement from the company.

"We are excited to bring our entire suite of products to New Mexico, including our QuantaCann2™ - an advanced cloud-based potency monitoring system," said David Lampach, CEO and cofounder of Steep Hill. "This will enable the state to meet its THC and CBD testing requirements, while also providing regulators with a real time window into the marketplace."

The State of New Mexico requires regular testing be done in a Department of Health approved laboratory as the only acceptable method to determine the quality, purity and potency required for the sale of medical cannabis products.

For more information about cannabis testing, you can visit the Steep Hill website: http://steephill.com

About Steep Hill

Syndicate content